Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Drugs with Dosage: PELLETS

Email this page to a colleague

« Back to Dashboard

Drugs with Dosage: PELLETS

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration	Dosage
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial			Y	⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial			Y	⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial			Y	⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-002	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial	PELLETS;ORAL
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-002	Jun 21, 2021		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial	PELLETS;ORAL
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration	>Dosage

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Boehringer Ingelheim

Merck

Dow

Baxter

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.